CAS and Novartis Partnered to Enhance Reaction Data

The collaboration aims to standardize research data to support AI-driven drug discovery workflows.

Updated on Sept. 29, 2026 in Chemistry

Bold flat-color editorial illustration of a complex molecular lattice structure, representing the organization of chemical data for research. — CAS and Novartis Biomedical Research have entered a partnership to standardize experimental chemical data, aiming to accelerate AI-enabled drug discovery workflows. AI Illustration. Upload story photo >

Live Poll

Do you believe using AI to manage scientific research data will improve drug discovery?

CAS, a division of the American Chemical Society, has announced a collaboration with Novartis Biomedical Research to improve the accessibility of experimental reaction data. The project will leverage the existing CAS SciFinder architecture to build a custom discovery platform.

Why it matters

This initiative seeks to address data fragmentation by organizing internal research records, potentially accelerating AI-enabled drug discovery. It reflects a broader industry push to make siloed laboratory data machine-readable for large language models and agentic AI.

The initiative utilizes CAS data transformation services to curate Novartis research stored across electronic lab notebooks and shared drives. This system draws on the CAS Content Collection, which currently hosts over 160 million scientist-curated reactions.

The players

CAS

A division of the American Chemical Society that maintains a massive repository of curated chemical reaction data and research tools.

Novartis Biomedical Research

The research arm of the global pharmaceutical company currently digitizing internal laboratory workflows.

The details

CAS will deploy data transformation services via its Intelligence Hub to standardize heterogeneous datasets from Novartis. By organizing these records, the partners aim to build a custom search platform atop the established CAS SciFinder architecture, which uses structured data for chemical searching. This architecture is designed to support future implementations of large language models and agentic AI, which are autonomous systems capable of executing complex laboratory tasks.

CAS announced the collaboration with Novartis on September 29, 2026.

The Tech Race

The partnership follows the technical foundation of the CAS SciFinder architecture to modernize data access in chemical research. It represents a pivot toward building domain-specific, AI-ready datasets that compete with general-purpose tools for pharmaceutical discovery.

Researchers at Novartis will soon interface with a unified search platform, potentially replacing manual searches through legacy lab reports. The long-term impact includes faster experimental design cycles as the system prepares internal data for integration with future generative AI tools.

The takeaway

This collaboration highlights the growing necessity of standardizing disparate lab data to unlock the potential of agentic AI. Stakeholders should watch for future technical milestones, such as the pilot rollout of the custom search platform for Novartis research teams.